Alexion reports positive asfotase alfa interim results for infants
This article was originally published in Scrip
Executive Summary
Investors had another ho-hum reaction to good news for asfotase alfa from Alexion Pharmaceuticals after the company reported interim data from an open-label Phase II study that showed statistically significant improvements in skeletal mineralization after 24 weeks of treatment for 13 infants (p=0.001) suffering from the life-threatening genetic disease hypophosphatasia (HPP).